Ethypharm to acquire Altan Pharma, entering the Spanish market and enhancing its Critical Care portfolio and R&D pipeline prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SAINT-CLOUD, France, May 19, 2021 /PRNewswire/ Ethypharm announces today that it has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. This agreement confirms Ethypharm s commitment to patients whose daily life is altered by pain.
Migraine is one of the most common neurological conditions, affecting about 12% of the population in Europe. In the management of acute migraine attacks, many medicines are already available. However, patients may not be always satisfied with the efficacy of existing treatments and some may have concerns about their potential side effects. There is therefore a need to offer further alternatives to patients suffering from acute migraine attacks.
Ethypharm establishes direct presence in Italy
USA - English
Share this article
SAINT-CLOUD, France, April 23, 2021 /PRNewswire/
Ethypharm announces today that it now has a fully established affiliate to operate directly in Italy, the third largest pharmaceutical market in Europe. Under the leadership of Bruno Rago, Ethypharm Italy will reinforce the group s commercial footprint in Europe, notably in its core therapeutic area of the Central Nervous System.
Founded in 1977 in France, Ethypharm is a specialty pharmaceutical company with solid roots in Europe and China. After its establishment in the United Kingdom and Germany in 2015, the addition of a direct presence in Italy is a major milestone to strengthen the group s commercial platform in Europe. Ethypharm Italy Srl is headquartered in Padova and will serve both the hospital and retail pharmacy channels.
Ethypharm establishes direct presence in Italy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Ethypharm ready to bring to patients world-leading digital therapies for depression and addiction
Ethypharm announces today that it has acquired exclusive rights for two CE-marked digital therapies, deprexis and vorvida
, developed by GAIA AG (GAIA), a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area of the Central Nervous System (CNS) where there are significant unmet needs.
30 million European individuals suffer from depression. The burden of mental disorders is growing, with significant impacts on health and major social and economic consequences. The ongoing COVID-19 pandemic is leading to an increase in cases of depression and alcohol use disorders (AUD). In parallel, to address the pandemic, digital health technologies have been adopted at a fast pace to help maintain an appropriate care of patients.